Psychiatry
Systematic Review | Cognitive behavioral therapy (group) for schizophrenia.
25 Jul, 2022 | 12:48h | UTCCognitive behavioural therapy (group) for schizophrenia – Cochrane Library
Summary: Group cognitive behavioural therapy for schizophrenia – Cochrane Library
RCT | Flexible buprenorphine/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder.
22 Jul, 2022 | 11:38h | UTCNews Release: Opioid use disorder: Flexible treatment at home proves effective – University of Montreal Hospital Research Centre
Systematic Review | Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
22 Jul, 2022 | 11:24h | UTC
Commentary on Twitter
New review published on 'Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults'! Read it on @CochraneLibrary at https://t.co/aaFmEAP8c2 pic.twitter.com/scnKmlcHh1
— CochraneDPLP (@CochraneDPLP) February 28, 2022
M-A | Family interventions for relapse prevention in schizophrenia.
22 Jul, 2022 | 11:22h | UTCFamily interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary: Almost All Family Interventions Can Prevent Relapse in Schizophrenia – HealthDay
Commentary on Twitter
"We suggest that policy makers integrate family interventions into standard clinical practice. If resources are limited, simple family psychoeducation should be offered."
New Researchhttps://t.co/9vXvvjwd5Z
— The Lancet Psychiatry (@TheLancetPsych) January 28, 2022
Comprehensive review finds little evidence that depression is caused by an imbalance of serotonin in the brain.
21 Jul, 2022 | 13:29h | UTCNews Release: No evidence that depression is caused by low serotonin levels, finds comprehensive review – University College London
Commentary from the authors: Depression is probably not caused by a chemical imbalance in the brain – new study – The Conversation
Other commentaries:
Expert reaction to a review paper on the ‘serotonin theory of depression’ – Science Media Centre
Little evidence that chemical imbalance causes depression, UCL scientists find – The Guardian
Systematic Review | Patient-level interventions to reduce alcohol-related harms in low- and middle-income countries.
21 Jul, 2022 | 12:43h | UTC
Commentary on Twitter
1/2
A very productive course on systematic reviews at @DukeGHI resulted in a study that summarized findings on the effectiveness of interventions to reduce alcohol-related harms in LMICs. Check it out!
➡️https://t.co/LtQhCx6Kh3 pic.twitter.com/WksDicEqpy— GEMINI Research Center (@GEMINI_Research) April 12, 2022
M-A | Effectiveness of interventions to improve medication adherence in adults with depressive disorders.
21 Jul, 2022 | 12:33h | UTC
RCT | Therapist-guided internet-based psychodynamic therapy vs. cognitive behavioral therapy for adolescent depression.
20 Jul, 2022 | 11:54h | UTC
Commentary on Twitter
NEW Research: "Therapist-guided internet-based #psychodynamic therapy versus #cognitivebehaviouraltherapy for adolescent #depression in Sweden: a randomised, clinical, non-inferiority trial". @Stockholm_Unihttps://t.co/wZ15f80VSg pic.twitter.com/B78TJlrDVL
— The Lancet Digital Health (@LancetDigitalH) July 6, 2022
M-A | Efficacy and tolerability of cranial electrotherapy stimulation in the treatment of anxiety.
20 Jul, 2022 | 11:42h | UTC
Commentary on Twitter
MA: cranial electrotherapy stimulation, a portable device, reduced anxiety symptoms vs. control group [g= −0.625; −0.952 to −0.298]. CES reduced both primary and secondary anxiety (g= −1.218 and −0.334, respectively). No severe AEs were reported https://t.co/Z9f9vnvmVD pic.twitter.com/wyN91oz7Mi
— PfOL (@psychopharmacol) June 15, 2022
Systematic Review | Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms.
19 Jul, 2022 | 13:25h | UTCAntipsychotics for schizophrenia spectrum disorders with catatonic symptoms – Cochrane Library
RCT | Effect of psychiatric advance directives facilitated by peer workers on compulsory admission among people with mental illness.
19 Jul, 2022 | 13:22h | UTCCommentary: Advance Directives for Psychiatric Care Reduce Compulsory Admissions – Medscape (free registration required)
Commentary on Twitter
A RCT found that psychiatric advance directives facilitated by peer-workers were associated with a significant decrease in compulsory readmission and an increase in recovery outcomes among adults living with SCZ, BP-I or SCZ-Aff. https://t.co/ICcwE1RYyJ #EPA2022
— JAMA Psychiatry (@JAMAPsych) June 6, 2022
RCT | Effect of Dextromethorphan plus Bupropion vs. Bupropion alone in major depressive disorder.
19 Jul, 2022 | 13:19h | UTCEffect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial – American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary: Dextromethorphan-Bupropion Significantly Improves Depression Symptoms, Study Finds – Psychiatry News Alert
Systematic Review | Stimulant and non‐stimulant drug therapy for people with attention deficit hyperactivity disorder and epilepsy.
19 Jul, 2022 | 13:24h | UTC
Population-level risks of alcohol consumption by amount, geography, age, sex, and year | A systematic analysis for the Global Burden of Disease Study 2020.
18 Jul, 2022 | 11:39h | UTCCommentaries:
Alcohol is never good for people under 40, global study finds – The Guardian
Global study finds surprising results for alcohol consumption – CNN
No alcohol safe to drink, global study confirms – BBC
Commentary on Twitter (thread – click for more)
New #GBDStudy suggests alcohol consumption carries significant health risks and no benefits for young people; some older adults may benefit from drinking a small amount.
Find out more: https://t.co/nn3V68KNIX @IHME_UW pic.twitter.com/i5wz2AR94w
— The Lancet (@TheLancet) July 14, 2022
Network M-A | Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults.
18 Jul, 2022 | 11:41h | UTC
M-A | Vortioxetine for the treatment of major depressive disorder in adults.
15 Jul, 2022 | 12:15h | UTC
RCT | Pharmacogenomic testing for drug-gene interactions provides little benefit for the remission of symptoms in major depressive disorder.
14 Jul, 2022 | 13:05h | UTCEffect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Pharmacogenomic Testing for Next-Step Antidepressant Selection: Still a Work in Progress – JAMA (free for a limited period)
Commentary: Does Pharmacogenomic Testing Improve Outcomes in Major Depressive Disorder? — The evidence is unclear – MedPage Today (free registration required)
Commentary on Twitter
In this randomized clinical trial, pharmacogenomic testing for drug-gene interactions in major depressive disorder reduced prescription of medications with predicted drug-gene interactions but had small and nonpersistent effects on symptom remission. https://t.co/Z2OIK3h1Bo pic.twitter.com/8eKSipfBFN
— JAMA (@JAMA_current) July 12, 2022
Brain stimulation may reduce negative symptoms of schizophrenia, meta-analysis suggests.
12 Jul, 2022 | 11:56h | UTCOriginal Study: Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia: A Systematic Review and Network Meta-analysis – JAMA Psychiatry (link to abstract – $ for full-text)
Author Interview: Assessment of Noninvasive Brain Stimulation Interventions for Negative Symptoms of Schizophrenia
Review | How to evaluate and care for the suicidal patient in the emergency department.
12 Jul, 2022 | 11:55h | UTCHow to evaluate and care for the suicidal patient in the ED – emDocs
Review | Anorexia nervosa and the gastrointestinal tract.
11 Jul, 2022 | 12:08h | UTCAnorexia nervosa and the gastrointestinal tract – Frontline Gastroenterology (free for a limited period)
Commentaries on Twitter
Summary of GI manifestations of anorexia nervosa #FGDebate https://t.co/hwsqfBBrr9@GastroNW pic.twitter.com/Mp1IHfpGKc
— Frontline Gastro (@FrontGastro_BMJ) October 13, 2021
Table summary of GI manifestations in anorexia nervosa, including rare symptoms #FGDebate @GastroNW https://t.co/hwsqfBBrr9 pic.twitter.com/Thqj1xKLEj
— Frontline Gastro (@FrontGastro_BMJ) October 13, 2021
RCT | Effect of electroacupuncture on insomnia in patients with depression.
8 Jul, 2022 | 11:45h | UTCInvited Commentary: Effects of Electroacupuncture for Depression-Related Insomnia – JAMA Network Open
Commentary on Twitter
This randomized clinical trial found that an 8-weeek electroacupuncture with standard care improved sleep quality for patients with insomnia and depression, compared with sham acupuncture and/or standard care. https://t.co/nacnxEI4Ik
— JAMA Network Open (@JAMANetworkOpen) July 7, 2022
RCT | Balovaptan no better than placebo for social communication in childhood autism spectrum disorder.
8 Jul, 2022 | 11:38h | UTC
Commentary on Twitter
In this RCT, balovaptan did not demonstrate efficacy in improvement of socialization and communication in pediatric autism spectrum disorder (ASD), highlighting challenges faced in #ASD trial design, such as outcome measure sensitivity & placebo response. https://t.co/FFAJeu5xv0
— JAMA Psychiatry (@JAMAPsych) July 6, 2022
RCT | Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military.
8 Jul, 2022 | 11:26h | UTCDose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial – Neuropsychopharmacology (if the link is paywalled, try this one)
Commentary on Twitter
Glad to see this work published. Contrary to predictions from small studies, #ketamine failed in the largest #PTSD clinical trial.
Future studies should test the lower dose and 3x/wk. @npp_journal @YalePsych @bcmhouston @netteaverillhttps://t.co/7NcFsNTMKw
— Chadi Abdallah (@ChadiAbdallah3) January 19, 2022
M-A | Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer’s disease.
7 Jul, 2022 | 12:34h | UTCCommentaries:
Registry-based cohort study | Neonatal morbidity after fetal exposure to antipsychotics.
6 Jul, 2022 | 11:24h | UTCNeonatal morbidity after fetal exposure to antipsychotics – BMJ Open